Johnson & Johnson (NYSE:JNJ) is Greatmark Investment Partners Inc.’s 9th Largest Position

Share on StockTwits

Greatmark Investment Partners Inc. grew its stake in Johnson & Johnson (NYSE:JNJ) by 1.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,296 shares of the company’s stock after buying an additional 1,217 shares during the quarter. Johnson & Johnson makes up 3.1% of Greatmark Investment Partners Inc.’s portfolio, making the stock its 9th biggest holding. Greatmark Investment Partners Inc.’s holdings in Johnson & Johnson were worth $10,348,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. Fisher Asset Management LLC grew its holdings in Johnson & Johnson by 2.6% during the 2nd quarter. Fisher Asset Management LLC now owns 11,841,121 shares of the company’s stock valued at $1,649,231,000 after buying an additional 301,124 shares in the last quarter. Clearbridge Investments LLC grew its holdings in Johnson & Johnson by 0.5% during the 1st quarter. Clearbridge Investments LLC now owns 9,628,443 shares of the company’s stock valued at $1,345,960,000 after buying an additional 48,582 shares in the last quarter. Nordea Investment Management AB grew its holdings in Johnson & Johnson by 14.2% during the 1st quarter. Nordea Investment Management AB now owns 8,709,414 shares of the company’s stock valued at $1,217,494,000 after buying an additional 1,079,751 shares in the last quarter. Thoroughbred Financial Services LLC grew its holdings in Johnson & Johnson by 14,147.0% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after buying an additional 3,986,071 shares in the last quarter. Finally, Swedbank grew its holdings in Johnson & Johnson by 5.5% during the 4th quarter. Swedbank now owns 4,001,754 shares of the company’s stock valued at $509,303,000 after buying an additional 209,665 shares in the last quarter. Institutional investors and hedge funds own 67.23% of the company’s stock.

In other Johnson & Johnson news, Director Marillyn A. Hewson purchased 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The stock was purchased at an average cost of $139.68 per share, with a total value of $419,040.00. Following the purchase, the director now owns 3,000 shares of the company’s stock, valued at $419,040. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.23% of the stock is currently owned by company insiders.

Shares of JNJ stock opened at $128.56 on Wednesday. Johnson & Johnson has a 52-week low of $121.00 and a 52-week high of $148.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33. The firm has a market capitalization of $337.10 billion, a P/E ratio of 15.72, a P/E/G ratio of 2.16 and a beta of 0.69. The stock has a 50 day moving average price of $131.66 and a 200 day moving average price of $136.44.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm had revenue of $20.56 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same period last year, the company earned $2.10 EPS. Johnson & Johnson’s quarterly revenue was down 1.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Johnson & Johnson will post 8.6 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date is Monday, August 26th. Johnson & Johnson’s dividend payout ratio is currently 46.45%.

Several research firms have weighed in on JNJ. Barclays began coverage on Johnson & Johnson in a report on Friday, June 21st. They set a “hold” rating and a $140.00 price target for the company. Goldman Sachs Group set a $169.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday. Morgan Stanley reaffirmed an “equal weight” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a research note on Tuesday. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $157.00 price objective (up from $152.00) on shares of Johnson & Johnson in a research note on Monday, May 6th. Finally, Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $150.60.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: What is cost of equity?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

OTCMKTS:PROSY  Now Covered by Analysts at Barclays
OTCMKTS:PROSY Now Covered by Analysts at Barclays
Exagen  Coverage Initiated by Analysts at Cowen
Exagen Coverage Initiated by Analysts at Cowen
Square  Receives New Coverage from Analysts at UBS Group
Square Receives New Coverage from Analysts at UBS Group
$248.92 Million in Sales Expected for ExlService Holdings, Inc.  This Quarter
$248.92 Million in Sales Expected for ExlService Holdings, Inc. This Quarter
XcelToken Plus  Tops 24-Hour Volume of $3,040.00
XcelToken Plus Tops 24-Hour Volume of $3,040.00
PDATA  Reaches 24-Hour Volume of $8,278.00
PDATA Reaches 24-Hour Volume of $8,278.00


© 2006-2019 Ticker Report